ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
42K |
6 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
155
|
42K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma
|
|
vrs37
|
155 |
42K |
7 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
155
|
42K
|
7
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
9.2K |
5 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
26
|
9.2K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
vrs37
|
26 |
9.2K |
7 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
26
|
9.2K
|
7
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
3 |
07/11/21 |
07/11/21 |
ASX - By Stock
|
16
|
11K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
2 |
03/11/21 |
03/11/21 |
ASX - By Stock
|
16
|
11K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
vrs37
|
16 |
11K |
3 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
16
|
11K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
vrs37
|
15 |
5.2K |
2 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Impact of COVID-19 on clinical trials
|
|
vrs37
|
15 |
5.2K |
2 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
15
|
5.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
IONIC
|
|
vrs37
|
14 |
4.7K |
1 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
14
|
4.7K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
A message to trolls
|
|
vrs37
|
12 |
3.9K |
6 |
03/09/21 |
03/09/21 |
ASX - By Stock
|
12
|
3.9K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Wonder Drug
|
|
vrs37
|
29 |
7.6K |
6 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
29
|
7.6K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Wonder Drug
|
|
vrs37
|
29 |
7.6K |
5 |
24/08/21 |
24/08/21 |
ASX - By Stock
|
29
|
7.6K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
vrs37
|
49 |
14K |
2 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results
|
|
vrs37
|
49 |
14K |
3 |
23/08/21 |
23/08/21 |
ASX - By Stock
|
49
|
14K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
vrs37
|
23 |
8.4K |
0 |
22/08/21 |
22/08/21 |
ASX - By Stock
|
23
|
8.4K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
vrs37
|
23 |
8.4K |
1 |
22/08/21 |
22/08/21 |
ASX - By Stock
|
23
|
8.4K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
vrs37
|
71 |
23K |
4 |
20/08/21 |
20/08/21 |
ASX - By Stock
|
71
|
23K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
vrs37
|
23 |
8.4K |
5 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
23
|
8.4K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
|
|
vrs37
|
28 |
9.6K |
2 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
28
|
9.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.7K |
2 |
10/08/21 |
10/08/21 |
ASX - By Stock
|
24
|
6.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.7K |
2 |
10/08/21 |
10/08/21 |
ASX - By Stock
|
24
|
6.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.7K |
2 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX and US Govt Peak Cancer Agency Announce Collaboration
|
|
vrs37
|
24 |
6.7K |
4 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
24
|
6.7K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
|
|
vrs37
|
28 |
9.6K |
4 |
05/08/21 |
05/08/21 |
ASX - By Stock
|
28
|
9.6K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Otto Buttula appointed to the Board of OncoSil
|
|
vrs37
|
20 |
13K |
0 |
23/07/21 |
23/07/21 |
ASX - By Stock
|
20
|
13K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Otto Buttula appointed to the Board of OncoSil
|
|
vrs37
|
20 |
13K |
2 |
22/07/21 |
22/07/21 |
ASX - By Stock
|
20
|
13K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Otto Buttula appointed to the Board of OncoSil
|
|
vrs37
|
20 |
13K |
1 |
20/07/21 |
20/07/21 |
ASX - By Stock
|
20
|
13K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Any progress in marketing in UK?
|
|
vrs37
|
12 |
7.2K |
3 |
20/06/21 |
20/06/21 |
ASX - By Stock
|
12
|
7.2K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Any progress in marketing in UK?
|
|
vrs37
|
12 |
7.2K |
1 |
20/06/21 |
20/06/21 |
ASX - By Stock
|
12
|
7.2K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Novartis Vision trial result
|
|
vrs37
|
18 |
6.1K |
3 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
18
|
6.1K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Novartis Vision trial result
|
|
vrs37
|
18 |
6.1K |
4 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
18
|
6.1K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil TGA regulatory update
|
|
vrs37
|
39 |
25K |
9 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
39
|
25K
|
9
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil TGA regulatory update
|
|
vrs37
|
39 |
25K |
2 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
39
|
25K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Lu-PSMA data
|
|
vrs37
|
6 |
1.9K |
3 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
6
|
1.9K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
4 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
41
|
13K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
4 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
41
|
13K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
3 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
6 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: New Independent Trial Data Supports Potential of Veyonda
|
|
vrs37
|
41 |
13K |
7 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
41
|
13K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
3 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
6 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
5 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
vrs37
|
32 |
10K |
5 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4C - quarterly
|
|
vrs37
|
6 |
3.7K |
0 |
02/05/21 |
02/05/21 |
ASX - By Stock
|
6
|
3.7K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Publications Positive Review of Veyonda in Chemotherapy
|
|
vrs37
|
9 |
3.1K |
5 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
9
|
3.1K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4C - quarterly
|
|
vrs37
|
6 |
3.7K |
2 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
6
|
3.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
vrs37
|
15 |
3.7K |
2 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
vrs37
|
15 |
3.7K |
2 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
vrs37
|
15 |
3.7K |
2 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
15
|
3.7K
|
2
|
|